London · Delayed Price · Currency is GBP · Price in GBX ValiRx Company Description
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom.
The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis.
It is also involved in the development of BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment of SARS-CoV2 infection; and CLX001, a peptide in a nanoparticle formulation for the treatment of triple negative breast cancer.
The company was founded in 2006 and is based in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Mark Eccleston |
Contact Details
Address: 20 Wenlock Road London, N1 7GU United Kingdom | |
| Phone | 44 115 7840026 |
| Website | valirx.com |
Stock Details
| Ticker Symbol | VAL |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BLH13C52 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark Eccleston | Chief Executive Officer |
| James Desler | Chief Financial Officer |
| Kumar Nawani | Chief Operating Officer |